Published in PLoS One on June 10, 2013
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29
Making vaccines "on demand": a potential solution for emerging pathogens and biodefense? Hum Vaccin Immunother (2013) 1.00
CD8 and CD4 T cells in west nile virus immunity and pathogenesis. Viruses (2013) 0.83
Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol (2014) 0.79
Of Mice and Men: Protective and Pathogenic Immune Responses to West Nile virus Infection. Curr Trop Med Rep (2015) 0.75
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet (2001) 6.49
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol (2010) 3.71
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med (2006) 3.57
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
Virus and antibody dynamics in acute west nile virus infection. J Infect Dis (2008) 2.84
Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev (2006) 2.75
CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol (2003) 2.69
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
T cell vaccines for microbial infections. Nat Med (2005) 2.59
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol (2008) 2.59
An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol (2003) 2.38
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol (1999) 2.22
Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol (2003) 1.88
The structural immunology of antibody protection against West Nile virus. Immunol Rev (2008) 1.63
Plumbing the sources of endogenous MHC class I peptide ligands. Curr Opin Immunol (2006) 1.47
Localization of the lectin, ERp57 binding, and polypeptide binding sites of calnexin and calreticulin. J Biol Chem (2002) 1.42
Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med (1994) 1.36
Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol (2011) 1.35
Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol (2004) 1.33
Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery. Biochemistry (2005) 1.26
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy (2009) 1.21
Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol (2010) 1.18
Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proc Natl Acad Sci U S A (2008) 1.18
Precursor frequency and competition dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice. J Immunol (2011) 1.13
Recent progress in West Nile virus diagnosis and vaccination. Vet Res (2012) 1.09
Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics (1997) 1.06
Associations between West Nile virus infection and symptoms reported by blood donors identified through nucleic acid test screening. Transfusion (2009) 1.04
Serologic surveillance for West Nile virus and other flaviviruses in febrile patients, encephalitic patients, and asymptomatic blood donors in northern Mexico. Vector Borne Zoonotic Dis (2010) 1.03
CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol (2008) 1.01
HLA-B15 peptide ligands are preferentially anchored at their C termini. J Immunol (1999) 0.96
Major histocompatibility complex class I molecules expressed with monoglucosylated N-linked glycans bind calreticulin independently of their assembly status. J Biol Chem (2004) 0.95
A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Methods (2004) 0.93
Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Rev Proteomics (2006) 0.90
Signatures of T cells as correlates of immunity to Francisella tularensis. PLoS One (2012) 0.90
Identification of CD8+ T cell epitopes in the West Nile virus polyprotein by reverse-immunology using NetCTL. PLoS One (2010) 0.89
A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS One (2011) 0.88
Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One (2010) 0.87
Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis (2011) 0.86
Improved definition of human leukocyte antigen frequencies among minorities and applicability to estimates of transplant compatibility. Transplantation (2007) 0.85
The resurgence of West Nile virus. Ann Intern Med (2012) 0.76
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis (2009) 3.31
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis (2013) 3.00
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA (2007) 2.59
Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol (2009) 2.24
Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis (2013) 2.15
DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J Immunol (2006) 1.78
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses (2011) 1.66
Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature (2002) 1.63
Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility. J Infect Dis (2006) 1.62
Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol (2011) 1.62
A high degree of HLA disparity arises from limited allelic diversity: analysis of 1775 unrelated bone marrow transplant donor-recipient pairs. Hum Immunol (2006) 1.58
3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol (2006) 1.58
Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol (2009) 1.57
Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS (2012) 1.54
Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. J Virol (2008) 1.54
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 1.51
Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis (2012) 1.50
Determination of cellular lipids bound to human CD1d molecules. PLoS One (2009) 1.49
Mauritian cynomolgus macaques share two exceptionally common major histocompatibility complex class I alleles that restrict simian immunodeficiency virus-specific CD8+ T cells. J Virol (2009) 1.45
Rapid and sensitive detection of respiratory virus infections for directed antiviral treatment using R-Mix cultures. J Clin Virol (2002) 1.43
Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS (2011) 1.42
Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis (2007) 1.41
B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev (2011) 1.41
Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol (2002) 1.36
Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev (2005) 1.35
Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol (2004) 1.33
Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One (2010) 1.32
Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol (2003) 1.30
Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery. Biochemistry (2005) 1.26
DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog (2006) 1.25
Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape. J Virol (2005) 1.25
The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. PLoS One (2011) 1.23
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol (2007) 1.22
When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epidemiol (2003) 1.22
Fidelity of SNP array genotyping using Epstein Barr virus-transformed B-lymphocyte cell lines: implications for genome-wide association studies. PLoS One (2009) 1.20
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood (2005) 1.19
Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol (2010) 1.18
Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes. Proc Natl Acad Sci U S A (2008) 1.18
Cutting edge: class I presentation of host peptides following HIV infection. J Immunol (2003) 1.18
The high frequency Indian rhesus macaque MHC class I molecule, Mamu-B*01, does not appear to be involved in CD8+ T lymphocyte responses to SIVmac239. J Immunol (2005) 1.17
Clinical evaluation of multiplex real-time PCR panels for rapid detection of respiratory viral infections. J Med Virol (2011) 1.16
Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2004) 1.14
A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood (2004) 1.14
Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Am J Epidemiol (2005) 1.12
Diagnosis of human metapneumovirus infection in immunosuppressed lung transplant recipients and children evaluated for pertussis. J Clin Microbiol (2006) 1.12
Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys (2006) 1.09
Comment on "characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study". J Acquir Immune Defic Syndr (2014) 1.09
Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS. PLoS Pathog (2007) 1.08
Degeneracy and repertoire of the human HIV-1 Gag p17(77-85) CTL response. J Immunol (2006) 1.08
HLA class I molecules consistently present internal influenza epitopes. Proc Natl Acad Sci U S A (2009) 1.07
Influenza and other respiratory virus infections in outpatients with medically attended acute respiratory infection during the 2011-12 influenza season. Influenza Other Respir Viruses (2014) 1.07
Selective induction of CTL helper rather than killer activity by natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination. J Immunol (2013) 1.06
Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr (2006) 1.06
The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One (2013) 1.06
Human CD8+ T cells specific for influenza A virus M1 display broad expression of maturation-associated phenotypic markers and chemokine receptors. Immunology (2005) 1.04
Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res (2008) 1.04
Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry (2004) 1.03
CD27 and CD57 expression reveals atypical differentiation of human immunodeficiency virus type 1-specific memory CD8+ T cells. Clin Vaccine Immunol (2006) 1.02
Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev (2012) 1.01
Value of a quality assessment program in optimizing cryopreservation of peripheral blood mononuclear cells in a multicenter study. Clin Vaccine Immunol (2013) 1.00
Demographic and clinical factors associated with persistent symptoms after West Nile virus infection. Am J Trop Med Hyg (2010) 1.00
T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope. J Virol (2009) 1.00
A charged amino acid residue in the transmembrane/cytoplasmic region of tapasin influences MHC class I assembly and maturation. J Immunol (2005) 1.00
Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood (2002) 0.99
Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol (2002) 0.99
Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant (2007) 0.98
Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. J Neurosci (2010) 0.98
Early HLA-B*57-restricted CD8+ T lymphocyte responses predict HIV-1 disease progression. J Virol (2012) 0.98
Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis (2003) 0.97
Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa. J Immunol (2006) 0.96
Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells. J Virol (2002) 0.96
Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells. J Virol (2009) 0.95
Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol (2008) 0.95
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol (2008) 0.94
Differential MHC class I expression in distinct leukocyte subsets. BMC Immunol (2011) 0.94
Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity. J Leukoc Biol (2008) 0.94